As of 2025-07-07, the Intrinsic Value of THC Biomed Intl Ltd (THC.CN) is 0.11 CAD. This THC.CN valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 0.02 CAD, the upside of THC Biomed Intl Ltd is 463.70%.
The range of the Intrinsic Value is 0.01 - 0.17 CAD
Based on its market price of 0.02 CAD and our intrinsic valuation, THC Biomed Intl Ltd (THC.CN) is undervalued by 463.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (36.92) - (6.13) | (10.43) | -52270.7% |
| DCF (Growth 10y) | (8.16) - (48.31) | (13.77) | -68952.9% |
| DCF (EBITDA 5y) | 0.01 - 0.17 | 0.11 | 463.7% |
| DCF (EBITDA 10y) | 0.26 - 0.76 | 0.57 | 2728.5% |
| Fair Value | -0.22 - -0.22 | -0.22 | -1,219.76% |
| P/E | (0.20) - (0.32) | (0.28) | -1477.3% |
| EV/EBITDA | (0.29) - 0.07 | (0.15) | -832.4% |
| EPV | (1.05) - (1.21) | (1.13) | -5734.5% |
| DDM - Stable | (0.80) - (5.06) | (2.93) | -14768.2% |
| DDM - Multi | (0.64) - (3.22) | (1.07) | -5464.1% |
| Market Cap (mil) | 1.64 |
| Beta | -0.29 |
| Outstanding shares (mil) | 81.97 |
| Enterprise Value (mil) | 6.24 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.68% |
| Cost of Debt | 5.00% |
| WACC | 4.22% |